Search patients...

Dr. Lee

Endocrinology

All patients

Casey Rodriguez

75F · BMI 38.2 · Tirzepatide pen · Pre-treatment

Precision Incretin Strategy Report

Casey Rodriguez

Age 75 · Female · BMI 38.2 · Prefilled Pen

Hyper-Sensitive Super-Responder Candidate

Gradual Adaptive Pacing (8–12 Week Gating)

This report synthesizes physiological brakes with biological accelerators to determine a personalized titration roadmap. Standard 4-week dose jumps are contraindicated for this patient. Velocity must be manipulated through duration, not dose granularity.

Key Action Items

5 directives · 1 time-critical

Ordered by urgency. The first item is timing-gated to the patient’s menstrual cycle — confirm the window before dosing.

Hormonal Timing Window

Do not dose today

High estrogen — 2.5× nausea

Recommended start (Day 18–24)

Menstrual

Luteal

Today is Day 13 — periovulatory estrogen peak. Starting now multiplies first-dose nausea ~2.5×. Hold 7 days and initiate on Day 20, once estrogen falls into the luteal trough.

Delay initiation 7 days

Time-critical

Start the 2.5 mg pen on Day 20 (luteal, low-estrogen) — not during today’s periovulatory peak.

Why Estrogen peaks at ovulation amplify GLP-1 nausea ~2.5×, and she already reports cycle-linked GI symptoms — stacking both risks severe first-dose emesis and early dropout.

Watch Re-confirm cycle day at the injection visit; reschedule if bleeding shifts the window.

From intakeQ1 FemaleQ3 Cycle-linked nausea — “Often”Q6 Very prone to nausea

Hold 2.5 mg · 8–12 weeks

Escalation gate

Do not advance to 5.0 mg until ≥8 weeks AND two consecutive GI-clear weeks.

Why Fast-returning hunger + baseline bloating = “Hungry Gut” phenotype: a strong responder that adapts slowly, so standard 4-week jumps overshoot tolerance.

Watch Reset the clock on any Grade ≥2 nausea or vomiting event.

From intakeQ7 Hunger returns 1–2hQ6 Very prone to nauseaQ8 Baseline bloatingQ14 GLP-1–naïve

Protein floor 1.5 g/kg/day

Daily floor

Set a daily protein target from today’s weight; pair with 2× weekly resistance training.

Why Could not rise from a chair without arms + age 75 → up to 39% of weight loss can come from lean mass.

Watch Repeat the chair-stand test each visit; hold dose if strength declines.

From intakeQ13 Cannot stand from chair unaided

Hydration floor 2.5 L/day

Daily floor

Target 2.5 L/day — 500 mL on waking; add oral electrolytes on any vomiting day.

Why Frequent standing dizziness signals orthostatic instability → syncope risk as appetite and intake drop.

Watch Screen for standing dizziness at every check-in.

From intakeQ9 Dizzy on standing — “Often”

Monitor anhedonia

Every visit

Re-score PHQ-2 each visit; lock the dose if hedonic tone flattens further.

Why Daily anhedonia alongside high food-noise and emotional eating means the dopaminergic reward brake is already active.

Watch Never trade mood for scale weight; worsening = dose-lock trigger.

From intakeQ12 Anhedonia — “Nearly every day”Q10 High food noiseQ11 Emotional eating — “Often”

Recommended Dosing Curve — Prefilled Pen

Week

Dose

Duration

Gate

1–12

2.5 mg

8–12 wk

GI tolerance confirmed

13–20

5.0 mg

8 wk

Strength floor verified

21–28

7.5 mg

8 wk

Mood + weight trajectory

29+

10 mg

Maintain

Clinician MED assessment

2.5 mg

5.0 mg

7.5 mg

10 mg

Standard protocol: 4-week jumps. This patient: 8–12 week gated escalation.

Biological Risk Indices

GI Sensitivity Index

Extreme

"Very Prone" motion sickness + prior nausea + "Hungry Gut" phenotype (hunger < 2h). Combined emetic burden is 3× population baseline.

Depletive Metabotype Risk

Critical

Age 75 + failed Chair Stand Test + gallstone history. Up to 39% of weight loss may come from lean mass without intervention.

Autonomic / Hydration Burden

High

"Often" dizzy upon standing + baseline fluid intake < 1 L/day. Syncopal event risk during initial appetite suppression.

Reward Pathway Vulnerability

Guarded

"Nearly every day" anhedonia (PHQ-2) + "Often" emotional eating. Dopaminergic brake active — dose lock rule applies.

Prescribing Intelligence

1. Resilient Titration — Fixed-Pen Logistics

"Hungry Gut" phenotype — prime responder but extreme GI shock risk

Hold 2.5 mg starter pen for 8–12 weeks (not standard 4-week jump)

Delay initiation 7 days — avoid periovulatory estrogen peak (2.5× nausea multiplier)

Pen constraint: velocity through duration, not dose. No 5.0 mg pen until 8-week GI clear.

2. Musculoskeletal Integrity — Strength Floor

Failed Chair Stand + age 75 → up to 39% of weight loss from muscle without intervention

Paradox: this demographic is 2× more likely to reach >15% TBWL (Super-Responder)

Mandate: Protein 1.5 g/kg/day + 2 days resistance training before approving next pen tier

Dose lock: hold escalation if chair stand declines — even if weight loss is active

3. Neurologic Reset — Reward Pathway

High food noise + emotional eating → strong candidate for Secondary Habit Freedom

PHQ-2 anhedonia baseline elevated ("Nearly every day") — dopaminergic brake active

Monitor mood at every check-in — if pleasure flattens, enforce Minimal Effective Dose lock

Do not prioritize scale weight over hedonic tone — anhedonia worsening is a dose-lock trigger

4. Pharmacological Audit

Evaluate current SSRIs — if depression stable, consider withdrawing weight-promoting agents

"Ozempic Face" risk — age 75 + high TBWL goal → proactive skin-elasticity referral if >10% loss

III

Safety Stack

Nausea Shield

Ginger 500 mg + Domperidone 10 mg TID pre-injection

Decay Delay

If GI flare → delay next pen 24–48h (do not skip full week)

Hydration Floor

2.5 L/day mandatory + oral electrolytes if vomiting

Motility Guard

Magnesium Citrate 400 mg nightly + fiber pre-treatment

Orthostatic Protocol

Two-stage rise (sit → pause 5s → stand). Fall risk: age + dizziness

Compound Risk

All 5 factors combined → cascading depletion risk in weeks 1–4

Generated by DoseGuide GLP Adaptive Intake · First Dose Health

For clinician review only · Not autonomous prescribing

Clinician Decision